Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463313) titled '6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors' on March 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Condition: Thymoma and Thymic Carcinoma

Intervention: Drug: Cyclophosphamide, Doxorubicin, and Cisplatin (CAP)

Recruitment Status: Not recruiting

Phase: Phase 2/Phase 3

Date of First Enrollment: March 2026

Target Sample Size: 116 ...